CM
AXSM icon

Castleark Management’s Axsome Therapeutics AXSM Stock Holding History

Castleark Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.41M Sell
22,083
-890
-4% -$193K 0.15% 157
2026
Q1 		$3.88M Sell
22,973
-1,280
-5% -$221K 0.13% 166
2025
Q4 		$4.43M Buy
24,253
+9,110
+60% +$1.27M 0.13% 165
2025
Q3 		$1.84M Sell
15,143
-22,897
-60% -$2.58M 0.05% 201
2025
Q2 		$3.97M Buy
38,040
+19,250
+102% +$2.04M 0.12% 142
2025
Q1 		$2.19M Buy
+18,790
New +$2.14M 0.08% 177
2024
Q2 		– Sell
-32,200
Closed -$2.57M – 275
2024
Q1 		$2.57M Buy
+32,200
New +$2.7M 0.11% 167

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Castleark Management's AXSM Position: Q2 2026 in Review

Castleark Management reduced its Axsome Therapeutics (AXSM) stake by 3.9% in Q2 2026, selling an estimated $193K and leaving 22,083 shares worth $5.41M. The position accounts for 0.15% of the portfolio, ranked #157.

Castleark Management first reported a position in AXSM in Q1 2024 and has held it in 7 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Castleark Management held 22,083 shares of Axsome Therapeutics worth $5.41M as of Q2 2026.
  • Castleark Management sold 890 Axsome Therapeutics shares in Q2 2026, an estimated $193K.
  • Axsome Therapeutics made up 0.15% of Castleark Management's portfolio in Q2 2026, its #157 holding.
  • Castleark Management first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.